According to Zacks, “Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company’s wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. “
Shares of NASDAQ STTK opened at $19.71 on Thursday. Shattuck Labs has a 12-month low of $17.15 and a 12-month high of $60.52. The stock has a market cap of $830.24 million and a PE ratio of -7.33. The company has a 50-day moving average of $20.05 and a 200 day moving average of $25.05.
A number of large investors have recently bought and sold shares of STTK. Royal Bank of Canada boosted its holdings in Shattuck Labs by 170.1% in the 1st quarter. Royal Bank of Canada now owns 1,110 shares of the company’s stock valued at $32,000 after purchasing an additional 699 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Shattuck Labs by 90.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,086 shares of the company’s stock valued at $60,000 after purchasing an additional 988 shares during the last quarter. Legal & General Group Plc boosted its holdings in Shattuck Labs by 185.7% in the 2nd quarter. Legal & General Group Plc now owns 3,954 shares of the company’s stock valued at $115,000 after purchasing an additional 2,570 shares during the last quarter. SG Americas Securities LLC acquired a new position in Shattuck Labs in the 2nd quarter valued at about $126,000. Finally, ProShare Advisors LLC acquired a new position in Shattuck Labs in the 2nd quarter valued at about $200,000. Institutional investors own 61.21% of the company’s stock.
About Shattuck Labs
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Recommended Story: Why does the United States have a lingering trade deficit?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.